Precision medicine: an intrahepatic cholangiocarcinoma with a novel RBPMS-MET fusion sensitive to crizotinib
Our case report strengthens the evidence that crizotinib may be a viable treatment option for patients with ICC with a c-MET tyrosine kinase fusion, necessitating additional clinical investigation.
Authors
- Jinpeng Liu (ORCID: https://orcid.org/0000-0002-4244-9784)
- Qianqian Duan
- S Li
- Xueqin Liu (ORCID: https://orcid.org/0000-0002-0487-1650)
- Yamin Zhang (ORCID: https://orcid.org/0000-0003-0727-0540)
- Wei Wan (ORCID: https://orcid.org/0000-0003-3047-9975)
- Rui Shen (ORCID: https://orcid.org/0000-0001-8491-0471)
- Weihu Xia
- Wuping Wang (ORCID: https://orcid.org/0000-0002-6791-2050)
- Yuan Tan
Institutions
- Simcere Pharmaceutical (China) (CN)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-11-19
- DOI
- https://doi.org/10.1093/oncolo/oyae340
- Citations
- 4
- Primary Topic
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.29